ETF recommends updating COVID-19 vaccines to target new JN.1 variant

The European Medicines Agency’s (EMA) Emergency Task Force (ETF)
has
recommended updating COVID-19 vaccines to target the new
SARS-CoV-2 variant JN.1 for the 2024/2025 vaccination campaign.

JN.1 differs from the XBB family targeted by previous updated
vaccines and has now surpassed the XBB variants to become the
most widely circulating variant worldwide.

In making its recommendation, the ETF consulted the World Health
Organization (WHO), international…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.